Developing a Biased Unmatched Bivalent Ligand (BUmBL) Design Strategy to Target the GPCR Homodimer Allosteric Signaling (cAMP over β-Arrestin 2 Recruitment) Within the Melanocortin Receptors.

MLA

Lensing, Cody J., et al. “Developing a Biased Unmatched Bivalent Ligand (BUmBL) Design Strategy to Target the GPCR Homodimer Allosteric Signaling (CAMP over β-Arrestin 2 Recruitment) Within the Melanocortin Receptors.” Journal of Medicinal Chemistry, vol. 62, no. 1, Jan. 2019, pp. 144–58. EBSCOhost, https://doi.org/10.1021/acs.jmedchem.8b00238.

APA

Lensing, C. J., Freeman, K. T., Schnell, S. M., Speth, R. C., Zarth, A. T., & Haskell-Luevano, C. (2019). Developing a Biased Unmatched Bivalent Ligand (BUmBL) Design Strategy to Target the GPCR Homodimer Allosteric Signaling (cAMP over β-Arrestin 2 Recruitment) Within the Melanocortin Receptors. Journal of Medicinal Chemistry, 62(1), 144–158. https://doi.org/10.1021/acs.jmedchem.8b00238

Chicago

Lensing, Cody J, Katie T Freeman, Sathya M Schnell, Robert C Speth, Adam T Zarth, and Carrie Haskell-Luevano. 2019. “Developing a Biased Unmatched Bivalent Ligand (BUmBL) Design Strategy to Target the GPCR Homodimer Allosteric Signaling (CAMP over β-Arrestin 2 Recruitment) Within the Melanocortin Receptors.” Journal of Medicinal Chemistry 62 (1): 144–58. doi:10.1021/acs.jmedchem.8b00238.